Ali Wahab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Wahab has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Ramesh Nadarajah
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds
5 shared publications Chris P Gale
Leeds Institute of Data Analytics, University of Leeds, Leeds, England, UK
4 shared publicationsAsad Bhatty
Leeds Institute of Data Analytics, University of Leeds, Leeds, England, UK
3 shared publications- Chris P. Gale
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds , Leeds
3 shared publications - Chris Wilkinson
Hull York Medical School, University of York, York, UK
3 shared publications - Jianhua Wu
Queen Mary University of London
3 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (5)
Specialist-led community-based cardio-kidney-metabolic-pulmonary care in high-risk individuals: multi-centre pragmatic prospective randomized open-label blinded endpoint trial
Aims: Pharmacological therapies that treat cardiovascular, kidney, metabolic, and pulmonary (CKMP) risk factors reduce the risk of major adverse cardiovascular events, but community-dwelling individuals may not receive all treatments to which they are eligible from non-specialists. This trial investigated if specialist-led care in the community increases the utilization of CKMP pharmacological interventions compared with usual care. Methods and results: This pragmatic prospective randomized open-label blinded endpoint trial included community-dwelling high-risk adults aged ≥30 years from 15 primary care sites in England. Participants were randomized 1:1 to an intervention of two clinic appointments (at baseline and ∼3 months) with a cardiology specialist at their primary care site to review and optimize CKMP risk factors in accordance with UK guidelines, or usual care. The primary outcome was the proportion of participants with initiation and/or increase in the dose of guideline-directed CKMP pharmacological therapies at 6 months after date of randomization. Between March 2025 and July 2025, 138 participants were randomized (68 intervention, 70 control); the median age was 76.6 years, and 52.9% were women. At 6 months after randomization, in the intervention arm, 42 of 68 (61.8%) patients received a CKMP pharmacological intervention compared with 16 of 70 patients (22.9%) in the control arm (odds ratio 5.4, 95% CI 2.5–12.3, P < 0.0001, absolute risk difference 38.9%, 95% CI 23.7–54.1%). Conclusion: Specialist-led care in the community for high-risk individuals increased the use of pharmacological interventions for CKMP risk factors compared to usual care.
- 2 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (5)
Open AccessSpecialist-led community-based cardio-kidney-metabolic-pulmonary care in high-risk individuals: multi-centre pragmatic prospective randomized open-label blinded endpoint trial
Aims: Pharmacological therapies that treat cardiovascular, kidney, metabolic, and pulmonary (CKMP) risk factors reduce the risk of major adverse cardiovascular events, but community-dwelling individuals may not receive all treatments to which they are eligible from non-specialists. This trial investigated if specialist-led care in the community increases the utilization of CKMP pharmacological interventions compared with usual care. Methods and results: This pragmatic prospective randomized open-label blinded endpoint trial included community-dwelling high-risk adults aged ≥30 years from 15 primary care sites in England. Participants were randomized 1:1 to an intervention of two clinic appointments (at baseline and ∼3 months) with a cardiology specialist at their primary care site to review and optimize CKMP risk factors in accordance with UK guidelines, or usual care. The primary outcome was the proportion of participants with initiation and/or increase in the dose of guideline-directed CKMP pharmacological therapies at 6 months after date of randomization. Between March 2025 and July 2025, 138 participants were randomized (68 intervention, 70 control); the median age was 76.6 years, and 52.9% were women. At 6 months after randomization, in the intervention arm, 42 of 68 (61.8%) patients received a CKMP pharmacological intervention compared with 16 of 70 patients (22.9%) in the control arm (odds ratio 5.4, 95% CI 2.5–12.3, P < 0.0001, absolute risk difference 38.9%, 95% CI 23.7–54.1%). Conclusion: Specialist-led care in the community for high-risk individuals increased the use of pharmacological interventions for CKMP risk factors compared to usual care.
- Open Access
- 26 June 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (11) , e2719-e2725
Identification, multimodal characterization, and clinical outcomes of pre-atrial fibrillation subclasses
- 26 June 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (11) , e2719-e2725
Open AccessIdentification, multimodal characterization, and clinical outcomes of pre-atrial fibrillation subclasses
- Open Access
- 27 May 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100592
A FeAsibility items Checklist for assessing implementation characTeristics of patient-reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): Development and evaluation
- 27 May 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100592
Open AccessA FeAsibility items Checklist for assessing implementation characTeristics of patient-reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): Development and evaluation
- Open Access
- 1 July 2025
- Published by BMJ in Open Heart
- Vol. 12 (2) , e003747
Cardiac magnetic resonance imaging-derived atrial fibrosis in patients with pre-atrial fibrillation
Introduction: Atrial fibrosis identified on cardiac magnetic resonance (CMR) imaging has been proposed as a preprocedural imaging biomarker for patient selection for rhythm control interventions in patients with atrial fibrillation (AF). Whether atrial fibrosis is present in patients considered as ‘pre-AF’ is unknown. Methods and results: We prospectively recruited 12 participants with pre-AF as defined by the Future Innovations in Novel Detection for Atrial Fibrillation (FIND-AF machine learning algorithm, without AF diagnosed during AF screening, and compared them to 25 participants with confirmed AF. All participants underwent CMR using a 3T system with left atrial fibrosis quantification and ADAS-3D left atrial image postprocessing software. Participants with pre-AF had smaller left atrial end-systolic (33.6±9.8 vs 43.0±17.0, p=0.003) and end-diastolic (16.5±8.7 vs 28.2±14.4, p=0.007) volumes, and higher left atrial ejection fraction (59.6±14.6 vs 40.7±17.5, p=0.005) than participants with AF. The extent of atrial fibrosis was not different between those with pre-AF and AF (borderzone (%) 5.2±5.0 vs 2.9±6.9, p=0.772; borderzone fibrosis (cm) 6.2±5.8 vs 6.8±10.7, p=0.927). Conclusion: CMR identifies atrial fibrosis before manifest AF in patients with pre-AF as defined by a machine learning algorithm.
- 1 July 2025
- Published by BMJ in Open Heart
- Vol. 12 (2) , e003747
Open AccessCardiac magnetic resonance imaging-derived atrial fibrosis in patients with pre-atrial fibrillation
Introduction: Atrial fibrosis identified on cardiac magnetic resonance (CMR) imaging has been proposed as a preprocedural imaging biomarker for patient selection for rhythm control interventions in patients with atrial fibrillation (AF). Whether atrial fibrosis is present in patients considered as ‘pre-AF’ is unknown. Methods and results: We prospectively recruited 12 participants with pre-AF as defined by the Future Innovations in Novel Detection for Atrial Fibrillation (FIND-AF machine learning algorithm, without AF diagnosed during AF screening, and compared them to 25 participants with confirmed AF. All participants underwent CMR using a 3T system with left atrial fibrosis quantification and ADAS-3D left atrial image postprocessing software. Participants with pre-AF had smaller left atrial end-systolic (33.6±9.8 vs 43.0±17.0, p=0.003) and end-diastolic (16.5±8.7 vs 28.2±14.4, p=0.007) volumes, and higher left atrial ejection fraction (59.6±14.6 vs 40.7±17.5, p=0.005) than participants with AF. The extent of atrial fibrosis was not different between those with pre-AF and AF (borderzone (%) 5.2±5.0 vs 2.9±6.9, p=0.772; borderzone fibrosis (cm) 6.2±5.8 vs 6.8±10.7, p=0.927). Conclusion: CMR identifies atrial fibrosis before manifest AF in patients with pre-AF as defined by a machine learning algorithm.
- Open Access
- 11 April 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 53, 101298
Systematic screening for atrial fibrillation with non-invasive devices: a systematic review and meta-analysis
- 11 April 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 53, 101298
Open AccessSystematic screening for atrial fibrillation with non-invasive devices: a systematic review and meta-analysis
- 1 January 2025
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 32 (1)
Screening for atrial fibrillation: a narrative review
Introduction The diagnosis of atrial fibrillation (AF) is made from an electrocardiogram (ECG) showing AF lasting for at least 30 seconds.1 The ECG characteristics of AF are irregularly irregular R–R intervals (where atrioventricular conduction is not impaired), absence of distinct repeating P-waves, and irregula ...
- 1 January 2025
- Published by Medinews (Cardiology), Ltd. in British Journal of Cardiology
- Vol. 32 (1)
Screening for atrial fibrillation: a narrative review
Introduction The diagnosis of atrial fibrillation (AF) is made from an electrocardiogram (ECG) showing AF lasting for at least 30 seconds.1 The ECG characteristics of AF are irregularly irregular R–R intervals (where atrioventricular conduction is not impaired), absence of distinct repeating P-waves, and irregula ...
- Open Access
- 9 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (7) , 900-909
Standardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
Aims: The lack of standardized definitions for heart failure outcome measures limits the ability to reliably assess the effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) aimed to produce a catalogue of internationally endorsed data definitions for heart failure outcome measures. Methods and results: Following the EuroHeart methods for the development of cardiovascular data standards, a working group was formed of representatives from the European Society of Cardiology Heart Failure Association and other leading heart failure experts. A systematic review of observational and randomized clinical trials identified current outcome measures, which was supplemented by clinical practice guidelines and existing registries for contemporary definitions. A modified Delphi process was employed to gain consensus for variable inclusion and whether collection should be mandatory (Level 1) or optional (Level 2) within EuroHeart. In addition, a set of complementary outcome measures were identified by the working group as of scientific and clinical importance for longitudinal monitoring for people with heart failure. Five Level 1 and two Level 2 outcome measures were selected and defined, alongside five complementary monitoring outcomes for patients with heart failure. Conclusion: We present a structured, hierarchical catalogue of internationally endorsed heart failure outcome measures. This will facilitate quality improvement, high quality observational research, registry-based trials, and post-market surveillance of medical devices.
- 9 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (7) , 900-909
Open AccessStandardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
Aims: The lack of standardized definitions for heart failure outcome measures limits the ability to reliably assess the effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) aimed to produce a catalogue of internationally endorsed data definitions for heart failure outcome measures. Methods and results: Following the EuroHeart methods for the development of cardiovascular data standards, a working group was formed of representatives from the European Society of Cardiology Heart Failure Association and other leading heart failure experts. A systematic review of observational and randomized clinical trials identified current outcome measures, which was supplemented by clinical practice guidelines and existing registries for contemporary definitions. A modified Delphi process was employed to gain consensus for variable inclusion and whether collection should be mandatory (Level 1) or optional (Level 2) within EuroHeart. In addition, a set of complementary outcome measures were identified by the working group as of scientific and clinical importance for longitudinal monitoring for people with heart failure. Five Level 1 and two Level 2 outcome measures were selected and defined, alongside five complementary monitoring outcomes for patients with heart failure. Conclusion: We present a structured, hierarchical catalogue of internationally endorsed heart failure outcome measures. This will facilitate quality improvement, high quality observational research, registry-based trials, and post-market surveillance of medical devices.
- Open Access
- 25 September 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (18) , 2099-2103
Phenotypic characterization of people at risk of atrial fibrillation: protocol for the FIND-AF longitudinal cohort study
Aims: The Future Innovations in Novel Detection of Atrial Fibrillation (FIND-AF) longitudinal cohort study is a multi-centre prospective cohort study of patients identified at risk of atrial fibrillation (AF). The aim of the FIND-AF longitudinal cohort study is to provide multi-modal phenotypic characterization of these patients. Methods and results: A total of 1955 participants identified as at risk of AF by the FIND-AF algorithm from primary care electronic health record (EHR) data, aged 30 years and above and eligible for oral anticoagulation, will be recruited between October 2023 and November 2024 to receive home-based intermittent electrocardiogram monitoring. About 500 participants without diagnosed AF will then undergo cross-sectional phenotypic characterization including physical examination, symptoms assessment, serum blood biomarkers and echocardiography, and non-stress cardiac magnetic resonance imaging. Longitudinal information about cardio–renal–metabolic–pulmonary outcomes will be ascertained from linkages to EHR data. The study is funded by the British Heart Foundation (CC/22/250026). The study has ethical approval (North West—Greater Manchester South Research Ethics Committee reference 23/NW/0180). Findings will be announced at relevant conferences and published in peer-reviewed journals in line with the funder’s open-access policy. Conclusion: The FIND-AF multi-centre prospective longitudinal cohort study aims to (i) provide evidence for the impact of comorbidities on AF genesis, (ii) uncover actionable targets to prevent AF, and (iii) act as a platform for cohort randomized clinical trials that investigate enhanced detection and prevention of AF.
- 25 September 2024
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 31 (18) , 2099-2103
Open AccessPhenotypic characterization of people at risk of atrial fibrillation: protocol for the FIND-AF longitudinal cohort study
Aims: The Future Innovations in Novel Detection of Atrial Fibrillation (FIND-AF) longitudinal cohort study is a multi-centre prospective cohort study of patients identified at risk of atrial fibrillation (AF). The aim of the FIND-AF longitudinal cohort study is to provide multi-modal phenotypic characterization of these patients. Methods and results: A total of 1955 participants identified as at risk of AF by the FIND-AF algorithm from primary care electronic health record (EHR) data, aged 30 years and above and eligible for oral anticoagulation, will be recruited between October 2023 and November 2024 to receive home-based intermittent electrocardiogram monitoring. About 500 participants without diagnosed AF will then undergo cross-sectional phenotypic characterization including physical examination, symptoms assessment, serum blood biomarkers and echocardiography, and non-stress cardiac magnetic resonance imaging. Longitudinal information about cardio–renal–metabolic–pulmonary outcomes will be ascertained from linkages to EHR data. The study is funded by the British Heart Foundation (CC/22/250026). The study has ethical approval (North West—Greater Manchester South Research Ethics Committee reference 23/NW/0180). Findings will be announced at relevant conferences and published in peer-reviewed journals in line with the funder’s open-access policy. Conclusion: The FIND-AF multi-centre prospective longitudinal cohort study aims to (i) provide evidence for the impact of comorbidities on AF genesis, (ii) uncover actionable targets to prevent AF, and (iii) act as a platform for cohort randomized clinical trials that investigate enhanced detection and prevention of AF.
- Open Access
- 30 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 5 (6) , 658-659
The power of data-driven ASSISTance in personalized testing for coronary artery disease
Ali Wahab, Ramesh Nadarajah; The power of data-driven ASSISTance in personalized testing for coronary artery disease, European Heart Journal - Digital Heal
- 30 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 5 (6) , 658-659
Open AccessThe power of data-driven ASSISTance in personalized testing for coronary artery disease
Ali Wahab, Ramesh Nadarajah; The power of data-driven ASSISTance in personalized testing for coronary artery disease, European Heart Journal - Digital Heal